ReviewTranslational lung cancer research2026
Advances in translational lung cancer research in 2025: a narrative review.
Review in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: By 2025, lung cancer translational research increasingly focuses on early detection, more precise stratification, and dynamic treatment selection. Against the backdrop of drug resistance and heterogeneity as major obstacles, clinically applicable diagnostic technologies and mechanism-driven therapeutic approaches are becoming increasingly critical for improving prognosis. This review aims to summarize the major advances in translational lung cancer research reported in 2025 and to discuss their potential clinical implications. Methods: We searched PubMed/MEDLINE and Web of Science databases to narratively synthesize five high-impact evidence areas in 2025: (I) early detection and minimal residual disease (MRD) monitoring; (II) biomarkers for targeted therapy and immunotherapy; (III) translational advances in novel therapeutic approaches; (IV) resistance mechanisms and breakthrough strategies; and (V) preclinical models and computational tools. Key Content and Findings: Significant advances have been made in multimodal early detection strategies. Liquid biopsy and complementary detection methods have advanced MRD monitoring, substantially enhancing risk stratification and longitudinal surveillance capabilities. Biomarker research has expanded from single markers to multi-marker combinations, enabling more precise response prediction and treatment sequencing guidance. In therapeutic domains, novel therapies like antibody-drug conjugates (ADCs) and bispecific antibodies demonstrate significant advantages across molecular subtypes and treatment stages, while first-line and early-stage regimens continue to be optimized. Resistance studies increasingly adopt reclassification and rematching models, clarifying mechanisms through tissue and liquid biopsies to inform rational combination therapies or next-generation inhibitor development. Concurrently, patient-derived models and functional models integrated with artificial intelligence (AI) analysis pipelines further strengthen the translational evidence chain, enhancing the interpretability of clinical decisions. Conclusions: The 2025 therapeutic landscape highlights patient-centered precision medicine framework encompassing early detection, scalable biomarkers, rational combination therapies, and real-time resistance adaptation mechanisms, continuously advanced through sophisticated models and computational tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.